BMND-02 is under clinical development by Biomind Labs and currently in Phase I for Fibromyalgia (Fibromyalgia Syndrome). According to GlobalData, Phase I drugs for Fibromyalgia (Fibromyalgia Syndrome) have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BMND-02’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dimethyltryptamine (BMND02) is under development for the treatment of fibromyalgia. It acts by targeting 5-hydroxytryptamine 2A receptor.
Biomind Labs overview
Biomind Labs, formely Crosswinds is an equity firm and asset manager that invests in the financial services sector. The company operates its business through a value chain including insurance, reinsurance and asset management sectors, among others. Its Monarch National Insurance Company, provides Monarch platform, which is a property and casualty insurance carrier operating in the US. Crosswind offers major subsidiaries such as Crosswinds AUM LLC, Crosswinds Monarch GP LLC, Crosswinds Re, Crosswinds Private Equity Partners (C.I.), GP, Crosswinds Private Equity Partners (C.I.), LP, and Crosswinds Investor Monarch LP, among others. The company operates in Canada and the US. Biomind Labs is headquartered in Toronto, Canada.
For a complete picture of BMND-02’s drug-specific PTSR and LoA scores, buy the report here.